Novartis Gets First LABA/LAMA Formulation Approved In Europe And Japan
This article was originally published in PharmAsia News
Novartis obtained approval in Japan for Ultibro inhalation capsule (indacaterol/glycopyrronium bromide) for maintenance therapy of adult COPD patients.
You may also be interested in...
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.